FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2782058498> ?p ?o ?g. }

• W2782058498 endingPage "2850" @default.
• W2782058498 startingPage "2850" @default.
• W2782058498 abstract "Background A standard chemotherapy regimen for relapse or refractory non-Hodgkin lymphoma (RR-NHL) is unexplained yet.Although platinum-based therapies, such as dexamethasone, high-dose cytarabine, and cisplatin and etoposide, methylprednisolone, high-dose cytarabine, and cisplatin (ESHAP), are the most commonly used second-line therapies for RR-NHL; nephrotoxicity is a potentially anxious side effect of platinum compounds. In addition, these regimens require a large volume of fluid replacement to prevent nephrotoxicity. ACES comprises carboplatin, 100 mg/m2 on days 1-4; etoposide, 80 mg/m2 on days 1-4; high-dose Ara-C, 2 g/m2 on day 5; and methylprednisolone, 500 mg/day for 5 days from the first day (Niitsu et. al. Eur J Haematol. 1996). However, ACES shows less renal toxicity and gastrointestinal symptoms by replacing cisplatin with carboplatin than that shown by ESHAP. The efficacy and safety of ACES are still unclear because clinical study on ACES regimen for lymphoma is limited. Therefore, we retrospectively evaluated the therapeutic effects and adverse events (AE) in RR-NHL patients who were treated with ACES regimens. Patients and methods We analyzed 116 refractory [patients who had not achieved complete response (CR) in the last chemotherapy (n = 78)] and relapse (n = 36) NHL patients who were treated with ACES regimen at our hospital from 2006 to 2016. ACES was performed at every 3 weeks. Among B-cell NHLs (n = 87), 80.4% of patients were treated with rituximab plus ACES. Patients 65 years of age or older were given two-thirds of the standard dose. The median age was 72 years (20-92 years) and median follow-up period was 386 days (29-3177 days). Histological analysis revealed diffuse large B-cell lymphoma (DLBCL) (n = 56), follicular lymphoma (FL) (n = 16), peripheral T-cell lymphoma (PTCL) (n = 19), and other NHLs (n = 25). The ACES regimen was administered as the second-line therapy in 71 (62.2%) patients, and more than third-line therapy in 36 (31%) patients. Sixteen patients underwent auto-PBSCT. We further analyzed the relationships between the clinical outcome [overall response rate (ORR), CR, disease-free survival, and overall survival (OS)], clinical data [sex, patient age (>65 years), performance status (>2), clinical stage (CS>III), IPI (>HI), FLIPI (>HI), number of prior therapies (>2), response to last chemotherapy, period from the last chemotherapy ( 5000/µl), lymphocyte count (>1000/µl), platelet count (>15000/µl), LDH (elevated or normal), sIL-2R (elevated or normal), and CRP (elevated or normal)] before initiating ACES regimen. AE were graded according to CTCAE version 4. Results The median number of cycles of ACES regimen was 2 (range: 1-11). Among all patients, ORR was 50% with CR 22.4%. ORR in DLBCL, FL, and PTCL were 50%, 68.8%, and 42.1%, and CR rates were 21.4%, 37.5%, and 16.6%, respectively. The overall median survival duration was 12.6 months; 3- and 5-year OS rates were 33.6% and 30.5%, respectively. Either of CS, elevated CRP, LDH, PS>2, number of previous therapies, response to last chemotherapy, sIL-2R, or period from the last chemotherapy was significantly associated with shorter OS (P= 0.026, P Hematological AE of grade 3 or higher included neutropenia in 90.5% and thrombocytopenia in 70.6% of patients; sepsis and pneumonia developed in two patients. Increased serum creatinine level of grade 3 or higher was observed only in 8.6% [grade 2 (n = 7), grade 3 (n = 3)]. Conclusion In this study, we analyzed a relatively large number of patients with NHL who were treated with ACES. Although this study included many patients with unfavorable factors such as older age, more than third-line therapy and refractory treatments before ACES, response rates, and OS were comparable with other salvage regimens including ESHAP. In ACES, carboplatin was administrated without continuous hydration, and renal toxicity was less than that in ESHAP. Therefore, we suggest that ACES is an option for treatment of RR-NHL. Disclosures No relevant conflicts of interest to declare." @default.
• W2782058498 created "2018-01-12" @default.
• W2782058498 creator A5009489272 @default.
• W2782058498 creator A5015381826 @default.
• W2782058498 creator A5017717309 @default.
• W2782058498 creator A5025201488 @default.
• W2782058498 creator A5025470783 @default.
• W2782058498 creator A5031845459 @default.
• W2782058498 creator A5037609364 @default.
• W2782058498 creator A5040125996 @default.
• W2782058498 creator A5047130109 @default.
• W2782058498 creator A5051620715 @default.
• W2782058498 creator A5068058602 @default.
• W2782058498 creator A5068481818 @default.
• W2782058498 creator A5070160413 @default.
• W2782058498 creator A5072195354 @default.
• W2782058498 creator A5076493229 @default.
• W2782058498 creator A5079292494 @default.
• W2782058498 creator A5079530630 @default.
• W2782058498 creator A5087987207 @default.
• W2782058498 date "2017-12-07" @default.
• W2782058498 modified "2023-09-29" @default.
• W2782058498 title "High-Dose Ara-C, Carboplatin, Etoposide, and Steroids (ACES) Is Effective in Relapse and Refractory Non-Hodgkin Lymphoma" @default.
• W2782058498 hasPublicationYear "2017" @default.
• W2782058498 type Work @default.
• W2782058498 sameAs 2782058498 @default.
• W2782058498 citedByCount "0" @default.
• W2782058498 crossrefType "journal-article" @default.
• W2782058498 hasAuthorship W2782058498A5009489272 @default.
• W2782058498 hasAuthorship W2782058498A5015381826 @default.
• W2782058498 hasAuthorship W2782058498A5017717309 @default.
• W2782058498 hasAuthorship W2782058498A5025201488 @default.
• W2782058498 hasAuthorship W2782058498A5025470783 @default.
• W2782058498 hasAuthorship W2782058498A5031845459 @default.
• W2782058498 hasAuthorship W2782058498A5037609364 @default.
• W2782058498 hasAuthorship W2782058498A5040125996 @default.
• W2782058498 hasAuthorship W2782058498A5047130109 @default.
• W2782058498 hasAuthorship W2782058498A5051620715 @default.
• W2782058498 hasAuthorship W2782058498A5068058602 @default.
• W2782058498 hasAuthorship W2782058498A5068481818 @default.
• W2782058498 hasAuthorship W2782058498A5070160413 @default.
• W2782058498 hasAuthorship W2782058498A5072195354 @default.
• W2782058498 hasAuthorship W2782058498A5076493229 @default.
• W2782058498 hasAuthorship W2782058498A5079292494 @default.
• W2782058498 hasAuthorship W2782058498A5079530630 @default.
• W2782058498 hasAuthorship W2782058498A5087987207 @default.
• W2782058498 hasConcept C126322002 @default.
• W2782058498 hasConcept C143998085 @default.
• W2782058498 hasConcept C2776694085 @default.
• W2782058498 hasConcept C2778041864 @default.
• W2782058498 hasConcept C2778119113 @default.
• W2782058498 hasConcept C2778239845 @default.
• W2782058498 hasConcept C2778336483 @default.
• W2782058498 hasConcept C2779338263 @default.
• W2782058498 hasConcept C2780653079 @default.
• W2782058498 hasConcept C2781214270 @default.
• W2782058498 hasConcept C2781413609 @default.
• W2782058498 hasConcept C2781451048 @default.
• W2782058498 hasConcept C71924100 @default.
• W2782058498 hasConcept C90924648 @default.
• W2782058498 hasConceptScore W2782058498C126322002 @default.
• W2782058498 hasConceptScore W2782058498C143998085 @default.
• W2782058498 hasConceptScore W2782058498C2776694085 @default.
• W2782058498 hasConceptScore W2782058498C2778041864 @default.
• W2782058498 hasConceptScore W2782058498C2778119113 @default.
• W2782058498 hasConceptScore W2782058498C2778239845 @default.
• W2782058498 hasConceptScore W2782058498C2778336483 @default.
• W2782058498 hasConceptScore W2782058498C2779338263 @default.
• W2782058498 hasConceptScore W2782058498C2780653079 @default.
• W2782058498 hasConceptScore W2782058498C2781214270 @default.
• W2782058498 hasConceptScore W2782058498C2781413609 @default.
• W2782058498 hasConceptScore W2782058498C2781451048 @default.
• W2782058498 hasConceptScore W2782058498C71924100 @default.
• W2782058498 hasConceptScore W2782058498C90924648 @default.
• W2782058498 hasLocation W27820584981 @default.
• W2782058498 hasOpenAccess W2782058498 @default.
• W2782058498 hasPrimaryLocation W27820584981 @default.
• W2782058498 hasRelatedWork W2183352065 @default.
• W2782058498 hasRelatedWork W2383294828 @default.
• W2782058498 hasRelatedWork W2386817084 @default.
• W2782058498 hasRelatedWork W2405898030 @default.
• W2782058498 hasRelatedWork W2495616845 @default.
• W2782058498 hasRelatedWork W2547967099 @default.
• W2782058498 hasRelatedWork W2548545961 @default.
• W2782058498 hasRelatedWork W2549408207 @default.
• W2782058498 hasRelatedWork W2550148098 @default.
• W2782058498 hasRelatedWork W2557062468 @default.
• W2782058498 hasRelatedWork W2561291203 @default.
• W2782058498 hasRelatedWork W2570138518 @default.
• W2782058498 hasRelatedWork W2571254774 @default.
• W2782058498 hasRelatedWork W2588069722 @default.
• W2782058498 hasRelatedWork W2600115829 @default.
• W2782058498 hasRelatedWork W2968223450 @default.
• W2782058498 hasRelatedWork W2979934944 @default.
• W2782058498 hasRelatedWork W2980789655 @default.
• W2782058498 hasRelatedWork W3000628660 @default.
• W2782058498 hasRelatedWork W3175889295 @default.
• W2782058498 hasVolume "130" @default.

• next